SCHEMBL4501209

SCHEMBL4501209

CCc1ccc2c(CCNC(C)=O)c[nH]c2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 13/20 0.67
MTNR1B P49286 13/20 0.67
CYP1A2 P05177 6/20 0.65
BLM P54132 3/20 0.65
MEN1 O00255 3/20 0.65
KMT2A Q03164 3/20 0.65
LMNA P02545 2/20 0.65
CYP2C19 P33261 2/20 0.65
PKM P14618 1/20 0.65
TSHR P16473 1/20 0.65
CYP3A4 P08684 4/20 0.61
CYP2D6 P10635 4/20 0.61
NOTUM Q6P988 3/20 0.61
KDM4E B2RXH2 3/20 0.61
HPGD P15428 3/20 0.61
NPSR1 Q6W5P4 2/20 0.61
ALDH1A1 P00352 2/20 0.61
MAPT P10636 1/20 0.61
IDO1 P14902 1/20 0.61
SPR P35270 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4498391 0.90 MTNR1A (0.72) MTNR1AMTNR1BCYP1A2BLMMEN1
SCHEMBL25842170 0.85 MTNR1A (0.62) MTNR1AMTNR1BCYP1A2BLMMEN1
SCHEMBL14390055 0.84 MTNR1A (0.49) MTNR1AMTNR1BCYP1A2BLMMEN1
SCHEMBL24460220 0.84 MTNR1A (0.80) MTNR1AMTNR1BCYP1A2BLMMEN1
SCHEMBL10289734 0.83 MTNR1A (0.51) MTNR1AMTNR1BCYP1A2BLMMEN1
SCHEMBL4488812 0.83 MTNR1A (0.81) MTNR1AMTNR1BCYP1A2BLMMEN1
SCHEMBL26451466 0.83 MTNR1A (0.69) MTNR1AMTNR1BCYP1A2BLMMEN1
SCHEMBL30630306 0.81 MTNR1A (1.00) MTNR1AMTNR1BCYP1A2BLMMEN1
SCHEMBL4490583 0.81 MTNR1A (1.00) MTNR1AMTNR1BCYP1A2BLMMEN1
SCHEMBL27084981 0.81 MTNR1A (0.81) MTNR1AMTNR1BCYP1A2BLMMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612099-B2 Vinylogous acid derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-03 US disclosed
CN-101321749-A Novel vinylogous acid derivatives HOFFMANN LA ROCHE (CH) 2008-12-10 CN disclosed
EP-1957483-A1 NOVEL VINYLOGOUS ACIDS DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-08-20 EP disclosed
WO-2007063010-A1 NOVEL VINYLOGOUS ACIDS DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-06-07 WO disclosed
US-20070129421-A1 Vinylogous acid derivatives HOFFMANN-LA ROCHE INC. 2007-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129421-A1 Vinylogous acid derivatives CMA1, TPSG1, TPSAB1 MTNR1A 454/4885MTNR1B 756/4885CYP1A2 488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.